Biomarkers of Progestin Therapy Resistance and Endometrial Hyperplasia Progression

Overview

Journal Am J Obstet Gynecol

Publisher Elsevier

Specialty Gynecology & Obstetrics

Date 2012 Jun 26

PMID 22727345

Citations 15

Authors

Kristen Upson

Kimberly H Allison

Susan D Reed

Carolyn D Jordan

Katherine M Newton

Elizabeth M Swisher

Jennifer A Doherty

Rochelle L Garcia

Affiliations

Soon will be listed here.

Abstract

Objective: We sought to identify biomarkers associated with progestin therapy resistance and persistence/progression of endometrial hyperplasia.

Study Design: We performed a nested case-control study among women with complex (n = 73) and atypical (n = 41) hyperplasia treated with oral progestin, followed up 2-6 months for persistence/progression. We evaluated index endometrial protein expression for progesterone receptor isoform A, progesterone receptor isoform B (PRB), PTEN, Pax-2, and Bcl-2. Odds ratios and 95% confidence intervals (CIs) were estimated.

Results: Among women with atypical hyperplasia, high PRB expression was associated with 90% decreased risk of persistence/progression (95% CI, 0.01-0.8). High expression of progesterone receptor A and PRB suggested decreased risk of persistence/progression (odds ratio, 0.1; 95% CI, 0.02-1.0). These findings were not observed among women with complex hyperplasia. No associations were found with PTEN, Pax-2, and Bcl-2 protein expression.

Conclusion: PRB expression shows promise as a biomarker of progestin response. Further research is warranted to understand how PRB expression may guide treatment decisions.

Citing Articles

Uterine-Conserving Treatment Options for Atypical Endometrial Hyperplasia and Early Endometrial Cancer.

Adjei N, Bowen M, Wilke R, Yates M, Westin S Curr Oncol Rep. 2024; 26(11):1367-1379.

PMID: 39361076 PMC: 11793993. DOI: 10.1007/s11912-024-01603-9.

End-to-end deep learning method for predicting hormonal treatment response in women with atypical endometrial hyperplasia or endometrial cancer.

Kahaki S, Hagemann I, Cha K, Trindade C, Petrick N, Kostelecky N J Med Imaging (Bellingham). 2024; 11(1):017502.

PMID: 38370423 PMC: 10868592. DOI: 10.1117/1.JMI.11.1.017502.

Weakly Supervised Deep Learning for Predicting the Response to Hormonal Treatment of Women with Atypical Endometrial Hyperplasia: A Feasibility Study.

Kahaki S, Hagemann I, Cha K, Trindade C, Petrick N, Kostelecky N Proc SPIE Int Soc Opt Eng. 2023; 12471.

PMID: 37159719 PMC: 10164282. DOI: 10.1117/12.2652912.

Progestin Resistance and Corresponding Management of Abnormal Endometrial Hyperplasia and Endometrial Carcinoma.

Lv M, Chen P, Bai M, Huang Y, Li L, Feng Y Cancers (Basel). 2022; 14(24).

PMID: 36551694 PMC: 9776943. DOI: 10.3390/cancers14246210.

MIG-6 Is Critical for Progesterone Responsiveness in Human Complex Atypical Hyperplasia and Early-Stage Endometrial Cancer.

Jeong O, Broaddus R, Lessey B, Risinger J, Hunter M, Kim T Int J Mol Sci. 2022; 23(23).

PMID: 36498921 PMC: 9738720. DOI: 10.3390/ijms232314596.

References

Bergeron C, Nogales F, Masseroli M, Abeler V, Duvillard P, Muller-Holzner E . A multicentric European study testing the reproducibility of the WHO classification of endometrial hyperplasia with a proposal of a simplified working classification for biopsy and curettage specimens. Am J Surg Pathol. 1999; 23(9):1102-8. DOI: 10.1097/00000478-199909000-00014. View

Tseng L, GURPIDE E . Effects of progestins on estradiol receptor levels in human endometrium. J Clin Endocrinol Metab. 1975; 41(2):402-4. DOI: 10.1210/jcem-41-2-402. View

Marsden D, Hacker N . Optimal management of endometrial hyperplasia. Best Pract Res Clin Obstet Gynaecol. 2001; 15(3):393-405. DOI: 10.1053/beog.2000.0184. View

Vereide A, Kaino T, Sager G, Orbo A . Bcl-2, BAX, and apoptosis in endometrial hyperplasia after high dose gestagen therapy: a comparison of responses in patients treated with intrauterine levonorgestrel and systemic medroxyprogesterone. Gynecol Oncol. 2005; 97(3):740-50. DOI: 10.1016/j.ygyno.2005.02.030. View

Trimble C, Kauderer J, Zaino R, Silverberg S, Lim P, Burke 2nd J . Concurrent endometrial carcinoma in women with a biopsy diagnosis of atypical endometrial hyperplasia: a Gynecologic Oncology Group study. Cancer. 2006; 106(4):812-9. DOI: 10.1002/cncr.21650. View

Vereide A, Kaino T, Sager G, Arnes M, Orbo A . Effect of levonorgestrel IUD and oral medroxyprogesterone acetate on glandular and stromal progesterone receptors (PRA and PRB), and estrogen receptors (ER-alpha and ER-beta) in human endometrial hyperplasia. Gynecol Oncol. 2005; 101(2):214-23. DOI: 10.1016/j.ygyno.2005.10.030. View

Peiro G, Diebold J, Baretton G, Kimmig R, Lohrs U . Cellular apoptosis susceptibility gene expression in endometrial carcinoma: correlation with Bcl-2, Bax, and caspase-3 expression and outcome. Int J Gynecol Pathol. 2001; 20(4):359-67. DOI: 10.1097/00004347-200110000-00008. View

Allison K, Tenpenny E, Reed S, Swisher E, Garica R . Immunohistochemical markers in endometrial hyperplasia: is there a panel with promise? A review. Appl Immunohistochem Mol Morphol. 2008; 16(4):329-43. DOI: 10.1097/PAI.0b013e318159b88e. View

Reed S, Newton K, Clinton W, Epplein M, Garcia R, Allison K . Incidence of endometrial hyperplasia. Am J Obstet Gynecol. 2009; 200(6):678.e1-6. PMC: 2692753. DOI: 10.1016/j.ajog.2009.02.032. View

10.

Sakuragi N, Salah-Eldin A, Watari H, Itoh T, Inoue S, Moriuchi T . Bax, Bcl-2, and p53 expression in endometrial cancer. Gynecol Oncol. 2002; 86(3):288-96. DOI: 10.1006/gyno.2002.6742. View

11.

Reed S, Newton K, Garcia R, Allison K, Voigt L, Jordan C . Complex hyperplasia with and without atypia: clinical outcomes and implications of progestin therapy. Obstet Gynecol. 2010; 116(2 Pt 1):365-373. PMC: 2949551. DOI: 10.1097/AOG.0b013e3181e93330. View

12.

Guzeloglu-Kayisli O, Kayisli U, Al-Rejjal R, Zheng W, Luleci G, Arici A . Regulation of PTEN (phosphatase and tensin homolog deleted on chromosome 10) expression by estradiol and progesterone in human endometrium. J Clin Endocrinol Metab. 2003; 88(10):5017-26. DOI: 10.1210/jc.2003-030414. View

13.

Utsunomiya H, Suzuki T, Ito K, Moriya T, Konno R, Sato S . The correlation between the response to progestogen treatment and the expression of progesterone receptor B and 17beta-hydroxysteroid dehydrogenase type 2 in human endometrial carcinoma. Clin Endocrinol (Oxf). 2003; 58(6):696-703. DOI: 10.1046/j.1365-2265.2003.01766.x. View

14.

Orbo A, Arnes M, Pettersen I, Larsen K, Hanssen K, Moe B . Down-regulated progesterone receptor A and B coinciding with successful treatment of endometrial hyperplasia by the levonorgestrel impregnated intrauterine system. Acta Obstet Gynecol Scand. 2010; 89(11):1438-46. DOI: 10.3109/00016349.2010.512068. View

15.

Vaskivuo T, Stenback F, Tapanainen J . Apoptosis and apoptosis-related factors Bcl-2, Bax, tumor necrosis factor-alpha, and NF-kappaB in human endometrial hyperplasia and carcinoma. Cancer. 2002; 95(7):1463-71. DOI: 10.1002/cncr.10876. View

16.

Graham J, Clarke C . Physiological action of progesterone in target tissues. Endocr Rev. 1997; 18(4):502-19. DOI: 10.1210/edrv.18.4.0308. View

17.

Smid-Koopman E, Blok L, Kuhne L, Burger C, Helmerhorst T, Brinkmann A . Distinct functional differences of human progesterone receptors A and B on gene expression and growth regulation in two endometrial carcinoma cell lines. J Soc Gynecol Investig. 2003; 10(1):49-57. View

18.

Zaino R, Kauderer J, Trimble C, Silverberg S, Curtin J, Lim P . Reproducibility of the diagnosis of atypical endometrial hyperplasia: a Gynecologic Oncology Group study. Cancer. 2006; 106(4):804-11. DOI: 10.1002/cncr.21649. View

19.

KENDALL B, Ronnett B, Isacson C, Cho K, Hedrick L, Diener-West M . Reproducibility of the diagnosis of endometrial hyperplasia, atypical hyperplasia, and well-differentiated carcinoma. Am J Surg Pathol. 1998; 22(8):1012-9. DOI: 10.1097/00000478-199808000-00012. View

20.

Shutter J, Wright Jr T . Prevalence of underlying adenocarcinoma in women with atypical endometrial hyperplasia. Int J Gynecol Pathol. 2005; 24(4):313-8. DOI: 10.1097/01.pgp.0000164598.26969.c3. View